Tango Therapeutics

“Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion” was recently published in the Journal of Medicinal Chemistry. TNG462 is a potent and selective MTA-cooperative PRMT5 inhibitor with favorable drug metabolism and pharmacokinetic properties. TNG462 as a single agent is currently under investigation in patients with NSCLC, mesothelioma, pancreatic cancer, and other solid non-CNS tumors in the Phase I/II clinical trial (NCT05732831). Read the full manuscript on Journal of Medicinal Chemistry here:

Join us this afternoon as Barbara Weber, M.D., President and CEO, participates in a fireside chat at the Leerink Global Healthcare Conference. Learn more: https://lnkd.in/eMGwe8_V

As six associates and two family members “sprint to the marathon” in support of the Boston Celtics Shamrock Foundation, this week we’re profiling Jacob McAllister, Staff Accountant, Finance. At Tango, Jacob actively participates in the accounting close process, finance operations as well as supports SEC compliance. Outside of his day job, Jacob is busy training for the Boston Marathon on behalf of the Shamrock Foundation which provides grassroots programming and strategic funding to local organizations serving at risk or at need youth populations. If you’d like to support Jacob and his cause, please donate here: https://lnkd.in/e58RGbwU

International Women’s Day provides an opportunity to recognize the more than 90 remarkable women of Tango – who make up more than half of the company – and the myriad ways they contribute to our leadership, culture and science: 👩⚕️ More than a third are managers or in leadership positions – including our CEO Barbara Weber, MD, CFO Daniella Beckman, Chief Development Operations Officer Heather DiBenedetto, Chief Human Resources Officer Julie Carretero and SVP, Head of Clinical Development Maeve Waldron-Lynch. 🔊 21 speak more than one language including Mandarin, French, Spanish and Marathi 🌎 They are global and diverse. 31 were born outside of the U.S. and 13 have worked in other countries including Thailand, Finland, Austria, Kenya and India as researchers, while enrolled in school, or as working professionals  🏫 More than half hold advanced degrees including two M.D.’s, 14 Ph.D.’s, two J.D.’s, two PharmD’s and 27 master’s degrees Each plays a critical role in advancing our mission to develop the next generation of precision cancer treatments. Thank you all for your contributions!  #IWD2025

As six associates and two family members “sprint to the marathon” in support of the Boston Celtics Shamrock Foundation, this week we’re profiling Jerrod Zimmer, Senior Analyst, Financial Planning & Analysis. At Tango, Jerrod partners with departments across the company to build budgets and analyze the company's financial data to provide insights for strategic decision making.  Outside of his day job, Jerrod is busy training for the Boston Marathon on behalf of the Shamrock Foundation which provides grassroots programming and strategic funding to local organizations serving at risk or at need youth populations. If you’d like to support Jerrod and his cause, please donate here: https://lnkd.in/e5ncGzuW

“Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor” was recently published in Organic Process Research & Development. The article describes the chemical process development for TNG908, an MTA-cooperative PRMT5 inhibitor that we have since stopped further development. Improvements were made to the original process in order to produce active pharmaceutical ingredient (API) with higher yields and better purity, resulting in a convergent, diastereoselective, safe, reproducible and robust commercial ready process. Read the full article in Organic Process Research & Development:

$TNGX news: Today we announced Q4 and full year 2024 financial results and recent business highlights, including: TNG462 granted Orphan Drug Designation (ODD) for treatment of pancreatic cancer, Investigational New Drug (IND) application for TNG456 cleared by the U.S. Food and Drug Administration (FDA) and a clinical collaboration established with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio (abemaciclib). Read the full announcement here: https://lnkd.in/e4x9Sc-6

As six associates and two family members “sprint to the marathon” in support of the Boston Celtics Shamrock Foundation, this week we’re profiling Gina Calvanese, Manager, Administration. At Tango, Gina supports our President and CEO and manages an admin team of seven. Outside of her day job, Gina is busy training for the Boston Marathon on behalf of the Shamrock Foundation which provides grassroots programming and strategic funding to local organizations serving at risk or at need youth populations. If you’d like to support Gina and her cause, please donate here: https://lnkd.in/eCf3hvwS

Happy Lunar New Year! At Tango, we celebrated with Asian-inspired food and drinks, cultural activities such as water coloring and mahjong and watched a traditional dragon dance performance and presentation by Sirimas Sudsakorn about the meaning of Lunar New Year and how her family celebrates. We hope the Year of the Snake provides you with wisdom, transformation, calmness and renewal!

 "MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design” was recently published in the Journal of Medicinal Chemistry. This article describes the discovery of novel compounds using structure-based design to switch the mechanism of binding of known SAM-cooperative PRMT5 inhibitors to an MTA-cooperative binding mechanism, allowing them to selectively target MTAP-deleted cancer cells. These compounds have proven to be important tools for the advancement of our understanding of the biology in the MTA-cooperative PRMT5 space. Read the full article in the Journal of Medicinal Chemistry: